Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo Nordisk Earnings Are Here. Wegovy Sales Beat Estimates for Weight Loss Drug.
Novo Nordisk posted solid quarterly results Wednesday before the market open.Sales came in at 71.3 billion Danish crowns ($10.3 billion) and diluted earnings per share of DKK 6.12 in the third quarter.
Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs, as it reported revenue and operating profit broadly in line with analysts’ expectations. The maker of the blockbuster Ozempic and Wegovy drugs has benefited in recent years from huge demand for its products.
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Novo Nordisk’s Blockbuster Wegovy Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Hosted on MSN2d
A new weight loss pill outperformed Novo Nordisk's version
Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which ...
Nature2d
How ‘miracle’ weight-loss drugs will change the world
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss ...
Time on MSN2d
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become ...
Today's Dietitian magazine8h
The Impact of New Weight Loss Drugs on Dietetics
The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?
Analysis-Americans Hungry for Weight-Loss Drugs Grapple With Supply and Insurance Hurdles
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
Newsweek on MSN1d
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed.
Can new weight loss drugs delay ageing?
What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An ...
News Medical on MSN2d
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.